292 terminated. 292 Phase 2, 94 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 292 | Terminated 292 |
| Phase 1 | 94 | Terminated 94 |
| Phase 3 | 7 | Terminated 7 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Modakafusp Alfa, Daratumumab - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-23 | 2026-01-30 |
| Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Terminated | Kite, A Gilead Company | 19 | 2022-11-01 | 2026-03-10 |
| Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ichnos Sciences SA | 29 | 2022-09-27 | 2025-01-17 |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Belantamab mafodotin - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2022-07-19 | 2025-01-28 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Pembrolizumab - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Terminated | Alfred Chung, MD | 3 | 2022-05-03 | 2025-01-15 |
| A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma Daratumumab, Pomalidomide, All-trans retinoic acid - Multiple Myeloma | Phase 2 | Terminated | Hackensack Meridian Health | 1 | 2022-05-02 | 2025-02-25 |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma PHE885 - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 146 | 2022-03-03 | 2026-01-13 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Selinexor, Clarithromycin, Pomalidomide - Myeloma Multiple, Myeloma | Phase 2 | Terminated | Weill Medical College of Cornell University | 4 | 2021-12-29 | 2023-10-25 |
| Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Belantamab Mafodotin, Cyclophosphamide and Dexamethasone - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | University of Maryland, Baltimore | 10 | 2021-12-03 | 2025-04-03 |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Descartes 08 - Myeloma Multiple | Phase 2 | Terminated | Cartesian Therapeutics | 13 | 2021-12-01 | 2024-10-08 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Gilead Sciences | 36 | 2021-11-09 | 2025-05-02 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Pfizer | 46 | 2021-10-27 | 2026-04-24 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma INCB000928 - Myelodysplastic Syndromes, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 22 | 2021-08-19 | 2025-10-22 |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma ALLO-605, ALLO-647, Fludarabine - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Allogene Therapeutics | 6 | 2021-06-06 | 2024-06-28 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma EMB-06 - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Shanghai EpimAb Biotherapeutics Co., Ltd. | 40 | 2021-05-20 | 2025-05-28 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies GEN3014, Daratumumab - Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | Genmab | 130 | 2021-03-09 | 2026-05-19 |
Showing 20 of 292. Sign in to see all of them.
Multiple Myeloma (247) · Neoplasms, Plasma Cell (42) · Lymphoma (41) · Waldenstrom Macroglobulinemia (40) · Recurrence (38) · Leukemia, Lymphocytic, Chronic, B-Cell (37) · Lymphoma, Non-Hodgkin (36) · Myelodysplastic Syndromes (35) · Leukemia (33) · Hodgkin Disease (32) · Lymphoma, Mantle-Cell (30) · Lymphoma, B-Cell, Marginal Zone (29) · Lymphoma, Follicular (29) · Lymphoma, Large B-Cell, Diffuse (28) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25)
Cardiovascular Diseases (292) · Hemic and Lymphatic Diseases (292) · Vascular Diseases (292) · Hemorrhagic Disorders (291) · Hematologic Diseases (285) · Immune System Diseases (281) · Blood Protein Disorders (280) · Immunoproliferative Disorders (280) · Neoplasms by Histologic Type (279) · Paraproteinemias (277) · Lymphoproliferative Disorders (274) · Neoplasms (268) · Neoplasms, Plasma Cell (237) · Lymphatic Diseases (88)
Dexamethasone (71) · Bortezomib (46) · Cyclophosphamide (34) · Calcium Dobesilate (31) · Lenalidomide (30) · Melphalan (23) · Rituximab (22) · pomalidomide (19) · fludarabine phosphate (18) · Filgrastim (17) · carfilzomib (16) · Tacrolimus (15) · Antilymphocyte Serum (13) · daratumumab (13) · fludarabine (12)
National Cancer Institute (NCI) (17) · Masonic Cancer Center, University of Minnesota (10) · Gilead Sciences (6) · Incyte Corporation (6) · NYU Langone Health (6) · Weill Medical College of Cornell University (6) · Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Hackensack Meridian Health (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5) · Oncotherapeutics (5) · University of Arkansas (5) · Washington University School of Medicine (5) · Amgen (4)
United States (245) · France (20) · Canada (17) · Spain (17) · Italy (14) · Germany (13) · United Kingdom (12) · Australia (11) · Denmark (8) · South Korea (8) · Czechia (7) · Greece (7) · Belgium (6) · China (5) · Japan (5)
James R Berenson, MD (4) · Amitabha Mazumder, MD (3) · Maurizio Zangari, MD (3) · Ravi Vij, M.D. (3) · Alfred Chung, MD (2) · Alfred Garfall, MD (2) · Fabio Ciceri, MD (2) · Fred Zheng, M.D. (2)
PMID 31527168, PMID 17579184, PMID 19118065, PMID 19179301, PMID 20067838, PMID 21403127, PMID 21874061, PMID 22080968, PMID 22430088, PMID 23205612, PMID 23426943, PMID 24241210, PMID 24658821, PMID 25784527, PMID 26139427, PMID 26220293, PMID 26384354, PMID 26968534, PMID 27599328, PMID 28140719, PMID 28461396, PMID 29141948, PMID 29567784, PMID 30032977, PMID 30123673, PMID 30190454, PMID 30230047, PMID 30293126, PMID 31215818, PMID 31229804, PMID 31443741, PMID 31471376, PMID 31851290, PMID 33150497, PMID 33171487, PMID 33357481, PMID 33554732, PMID 34398557, PMID 34551886, PMID 34818965, PMID 34951522, PMID 35176457, PMID 36269898, PMID 36460794, PMID 36639200, PMID 37290996, PMID 37399355, PMID 37646702, PMID 37970718, PMID 38517235
2017 (4), 2018 (4), P30CA015704 (4), P30CA015083 (3), P30CA016058 (3), U10CA021115 (3), 2008 (2), 2016 (2), 2019 (2), 2023 (2), P30CA022453 (2), U10CA032102 (2), 2014 (1), N01CM00070 (1), N01CM17003 (1)